NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Quant Mutual Fund - Quant Small Cap Fund | 7.47% |
| Ayushmat Ltd | 2.78% |
| Kotak Mahindra Life Insurance Company Ltd. | 2.17% |
| Bank of India Small Cap Fund | 1.63% |
| Capri Global Capital Limited | 1.09% |
| Document | Date |
|---|---|
| Annual report FY2026 GUJARAT THEMIS BIOSYN LIMITED - FY26 SUMMARY HEADLINE NUMBERS • Total Income: Rs. 168.25 crores (up from Rs. 153.23 crores in FY25) • Revenue from O | 2026-09-04 |
| Q1 FY27 earnings call GUJARAT THEMIS BIOSYN LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue from operations Q1 FY27: INR 43.8 crores vs INR 35.9 crores in Q1 FY26 — | 2026-08-14 |
| Investor presentation · Q1 FY27 GUJARAT THEMIS BIOSYN LIMITED – Q1 FY2026-27 INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: Rs. 43.8 crores, up 22.1% YoY (vs. Rs. 35.9 crores | 2026-08-07 |
| Quarterly results · Q1 FY27 GUJARAT THEMIS BIOSYN LIMITED – Q1 FY 2026-27 SUMMARY HEADLINE NUMBERS • Total Income (Q1 FY26-27): INR 4,392.16 lakhs (standalone), down from INR 4 | 2026-08-07 |
| Investor presentation · Q4 FY26 GUJARAT THEMIS BIOSYN LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 16,582.28 lakhs (up 10% from FY25's INR 15,079.99 lakhs) • EBI | 2026-06-29 |
| Quarterly results · Q4 FY26 DOCUMENT SUMMARY: GUJARAT THEMIS BIOSYN LIMITED HEADLINE NUMBERS • Document Date: 20th June, 2026 • Company: Gujarat Themis Biosyn Limited • Stock Sy | 2026-06-25 |
| Investor presentation | 2026-05-25 |
| Investor presentation | 2026-05-22 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.67 / share ex-date Sep 23, 2026 | 2026-09-23 |
| Announcement | Date |
|---|---|
| Acquisition of another business announced Gujarat Themis Biosyn Limited (GTBL) has completed its acquisition of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) for JPY 21.5 billion (approximately INR 1,220 crores). The deal was fund | 2026-09-18 |
| Acquisition of Sanofi's Global Anti-TB and Anti-Infective Portfolio Gujarat Themis Biosyn Limited announced the acquisition of Sanofi's global anti-tuberculosis (anti-TB) and anti-infective drug portfolio on April 23, 2026. This is a significant strategic mo | 2026-04-23 |
| Capacity addition announced Gujarat Themis Biosyn Limited has informed the Exchange about Capacity addition | 2025-10-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gujarat Themis Biosyn Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.